Synonyms: pVXc-486 | SPR720
Compound class:
Synthetic organic
Comment: Fobrepodacin (SPR720) is an orally administered prodrug that is being developed for the treatment of non-tuberculous mycobacterial pulmonary disease (NTM-PD) [3]. The active metabolite, SPR719, is a novel aminobenzimidazole antibacterial compound that is a dual Inhibitor of bacterial DNA gyrase and DNA topoisomerase 4 [1] .
|
|
Bioactivity Comments |
The active metabolite, SPR719, is a potent inhibitor in vitro of both drug-sensitive and drug-resistant Mycobacterium tuberculosis laboratory strains and clinical isolates (MIC against M. tuberculosis H37Rv is in the range of of 0.12-0.25 μg/ml) [2]. It also inhibits the growth of Mycobacterium abscessus, Mycobacterium avium Complex (MAC), and Mycobacterium kansasii. In the same study, fobrepodacin demonstrated more potent in vivo activity against M. tuberculosis than SPR719. |